Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: The impact of bronchodilator treatment

Internal Medicine Journal

Volumn 40, Issue 2, 2010, Pages 94-101

  Wood Baker, R ^a,b   Cochrane, B ^a,c,d   Naughton, M T ^e,f  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

^c CAMPBELLTOWN HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Bronchodilator agents; Cardiovascular disease; Chronic obstructive pulmonary disease

Indexed keywords

AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; METHYLXANTHINE DERIVATIVE; OXITROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANGINA PECTORIS; ARRHYTHMOGENESIS; ASTHMA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; MORBIDITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77749322361     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02109.x     Document Type: Review

References (63)

1. Access Economics Pty Limited. Economic impact of COPD and cost effective solutions. 2008. Contract No.: Document Number.
2. McKenzie DK, Frith PA, Burdon JG, Town GI. The COPDX plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2003. Med J Aust 2003 178 (Suppl S7 39.
3. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007 146 : 545 555. (Pubitemid 351650535)
4. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 178 : 332 338.
5. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005 128 : 2640 2646.
6. Sidney S, Sorel M, Quesenberry CP Jr., DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005 128 : 2068 2075.
7. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002 166 : 333 339.
8. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006 28 : 1245 1257.
9. Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997 52 : 43 7.
10. Hole D, Watt G, Davey-Smith G, Hart C, Gillis C, Hawthorne V. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br Med J 1996 313 : 711 715.
11. Sin D, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005 2 : 8 11. (Pubitemid 40562956)
12. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006 61 : 472 477.
13. Engstrom G, Hedblad B, Janzon L, Valind S. Respiratory decline in smokers and ex-smokers - an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk 2000 7 : 267 272.
14. Sin D, Man S. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003 107 : 1514 1519.
15. Lagrand W, Visser C, Hermens W, Niessen H, Verheugt F, Wolbink G-J. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999 100 : 96 102.
16. Kannel WB, Kannel C, Paffenbarger RS Jr., Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987 113 : 1489 1494.
17. Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001 164 : 597 601.
18. Sakamaki F, Satoh T, Nagaya N, Kyotani S, Nakanishi N, Ishida Y. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest 1999 116 : 1575 1581.
19. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998 113 : 576 583.
20. Serizawa T, Vogel WM, Apstein CS, Grossman W. Comparison of acute alterations in left ventricular relaxation and diastolic chamber stiffness induced by hypoxia and ischemia. Role of myocardial oxygen supply-demand imbalance. J Clin Invest 1981 68 : 91 102.
21. Sin DD, Wong E, Mayers I, Lien DC, Feeny D, Cheung H et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest 2007 131 : 156 163.
22. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996 348 : 567 572.
23. Meier C, Jick S, Derby L, Vasilakis C, Jick H. Acute respiratory - tract infections and risk of first - time acute myocardial infarction. Lancet 1998 351 : 1467 1471. (Pubitemid 28227037)
24. Clayton T, Thompson M, Meade T. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008 29 : 96 103.
25. Spodick D, Flessas A, Johnson M. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984 53 : 481 482.
26. Hudson LD, Kurt T, Petty T, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest 1973 63 : 661 665.
27. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995 98 : 272 277.
28. Holford F, Mithoefer J. Cardiac arrhythmias in hospitalised patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1973 208 : 879 885.
29. Rogers RM, Spear JF, Moore EN, Horowitz LH, Sonne JE. Vulnerability of canine ventricle to fibrillation during hypoxia and respiratory acidosis. Chest 1973 63 : 986 994.
30. Yildiz P, Akkaya V, Sozen A, Yildez A, Korkut F, Yilmaz V. Ventricular arrhythmias in patients with COPD are associated with QT dispersion. Chest 2002 122 : 2055 2061.
31. Tukek T, Yildez P, Akkaya V, Karan N, Atilgan D, Yilmaz V. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002 7 : 222 227.
32. Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008 87 : 319 328.
33. Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest 2001 120 : 1783 1790.
34. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in The Copenhagen City Heart Study. Eur J Respir Dis 2003 21 : 1012 1016. (Pubitemid 36675619)
35. Engstrom G, Wollmer P, Hedblad B, Juul-Moller S, Valind S, Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function. Circulation 2001 103 : 3086 3091.
36. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998 114 : 411 415.
37. Bouvy ML, Heerdink ER, De Bruin ML, Herings RM, Leufkens HG, Hoes AW. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000 160 : 2477 2480.
38. Panina-Bordignon P, Mazzeo D, Lucia P, D'Ambrosio D, Lang R, Fabbri L et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997 100 : 1513 1519.
39. Agarwal S, Marshall G. Beta-adrenergic modulation of human type- 1/type-2 cytokine balance. J Allergy Clin Immunol 2000 105 : 91 8.
40. Aldridge R, Hancox R, Taylor D, Cowan J, Winn M, Frampton C et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000 161 : 1459 1464.
41. Lazarus S, Boushey H, Fahy J, Chinchilli V, Lemanske R, Sorkness C et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001 285 : 2583 2593. (Pubitemid 32479898)
42. Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ. Nebulised salbutamol and angina. Br Med J (Clin Res Ed) 1982 285 : 796 797.
43. Chapman KR, Smith DL, Rebuck AS, Leenen FH. Hemodynamic effects of an inhaled beta-2 agonist. Clin Pharmacol Ther 1984 35 : 762 767.
44. Martelli NA, Raimondi AC, Lazzari JO. Asthma, cardiac arrhythmias, and albuterol aerosol. Chest 1986 89 : 192 194.
45. Seider N, Abinader EG, Oliven A. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest 1993 104 : 1070 1074.
46. Rossinen J, Partanen J, Stenius-Aarniala B, Nieminen MS. Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease. J Intern Med 1998 243 : 361 366.
47. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002 4 CD001495.
48. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008 16 (3 CD006363.
49. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008 8 (4 CD006923.
50. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006 21 : 1011 1019.
51. Campbell S, Criner G, Levine B, Simon S, Smith J, Orevillo C. Cardiac safety of formoterol 12 mcg twice daily in patients with chronic obstructive airways disease. Pulm Pharmacol Ther 2007 20 : 571 579.
52. Nelson H, Gross N, Levine B, Kerwin E, Rinehart M, Denis-Mize K. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicentre, randomised, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007 29 : 2167 2178.
53. Ferguson G, Funck-brentano C, Fisher T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 2003 123 : 1817 1824.
54. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008 149 : 380 390.
55. Joo MJ, Lee TA, Bartle B, van de Graaff WB, Weiss KB. Patterns of healthcare utilization by COPD severity: a pilot study. Lung 2008 186 : 307 312.
56. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 300 : 1439 1450.
57. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 359 : 1543 1544.
58. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008 336 : 924 926. (Pubitemid 351632017)
59. Ringbaek T, Viskum K. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma? Respir Med 2003 97 : 264 272.
60. Barr R, Bourbeau J, Camargo C. Inhaled Tiotropium for Stable Chronic Obstructive Pulmonary Disease (Protocol for a Cochrane Review). The Cochrane Library, Issue 4. Chichester : John Wiley & Sons, Ltd 2003.
61. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006 130 : 1695 1703.
62. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values. N Engl J Med 2009 360 : 1592 1595.
63. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 356 : 775 789.